Markets.com Logo
markets.com

FATE

$--
--%
1d
1w
1m

Analysis and statistics

  • Open
    1.1181$
  • Previous Close
    1.1181$
  • 52 Week Change
    3.54$
  • Day Range
    0.00$
  • 52 Week High/Low
    0.6611$ - 4.2$
  • Dividend Per Share
    --
  • Market cap
    128 M$
  • EPS
    -0.29
  • Beta
    2.245
  • Volume
    --

About

FATE.US represents Fate Therapeutics Inc., a biopharmaceutical company focused on the development of cell-based immunotherapies for cancer and immune disorders. The ".US" suffix indicates that the stock is traded on a United States stock exchange. Fate Therapeutics utilizes its induced pluripotent stem cell (iPSC) platform to generate engineered immune cell products, including natural killer (NK) cells and T cells, aiming to provide off-the-shelf, readily available therapies for patients. The company's pipeline includes several clinical-stage programs evaluating its cell therapy candidates in various cancer types.
markets.com
Dogecoin Price Forecast 2026–2030: Can DOGE Reach $1?

Dogecoin Price Forecast 2026–2030: Can DOGE Reach $1?

Julian Parker|--
Solana Price Prediction 2026, 2030 & 2040: How High Can SOL Go?

Solana Price Prediction 2026, 2030 & 2040: How High Can SOL Go?

Daniel Carter|--
Nvidia Q2 Earnings Preview: Can $92 Billion Revenue End NVDA’s Seven-Day Slide?

Nvidia Q2 Earnings Preview: Can $92 Billion Revenue End NVDA’s Seven-Day Slide?

Julian Parker|--
Ethereum (ETH) Price Prediction 2026-2030: Can ETH Break $3,000 After a 33% Weekly Rally?

Ethereum (ETH) Price Prediction 2026-2030: Can ETH Break $3,000 After a 33% Weekly Rally?

Julian Parker|--
Coinbase Stock Forecast 2026–2030: Can COIN Recover as Bitcoin Nears $80,000?

Coinbase Stock Forecast 2026–2030: Can COIN Recover as Bitcoin Nears $80,000?

Julian Parker|--
Cryptos shine again, USD on the edge

Cryptos shine again, USD on the edge

Darius Anucauskas|--
Samsung Stock Forecast: Can AI Memory Demand Offset the Latest Sell-Off?

Samsung Stock Forecast: Can AI Memory Demand Offset the Latest Sell-Off?

Julian Parker|--

Factors

Clinical Trial Results: Positive data boosts investor confidence; negative results can lead to significant price drops.

Regulatory Approval: FDA approval for Fate Therapeutics' cell therapies greatly impacts stock value.

Partnerships & Collaborations: Alliances with larger pharmaceutical companies can drive growth and stock price.

Market Sentiment: Overall investor attitude towards biotechnology and cell therapy affects FATE's valuation.

Financial Performance: Revenue, expenses, and cash flow impact investor perception of the company's long-term viability.

Competition: Advancements and approvals from competitors in the cell therapy space can put downward pressure on FATE's stock.

People Also Watch

Latest news

Bitcoin Price Surges Past $80,000 as ‘Debasement Trade’ Returns

Bitcoin Price Surges Past $80,000 as ‘Debasement Trade’ Returns

Julian Parker|--
Nvidia Stock Rises 2.19% as $280bn Earnings Swing Looms

Nvidia Stock Rises 2.19% as $280bn Earnings Swing Looms

Julian Parker|--
Oil Price Today: WTI Falls 2.6% to $80.20 on Hormuz Deal Hopes

Oil Price Today: WTI Falls 2.6% to $80.20 on Hormuz Deal Hopes

Julian Parker|--

Latest Education Articles

Top Meme Coins to Watch in 2026: A Trader’s Guide

Top Meme Coins to Watch in 2026: A Trader’s Guide

Julian Parker|--
XAU/USD Trading Hours in Dubai: When Does the Gold Market Open?

XAU/USD Trading Hours in Dubai: When Does the Gold Market Open?

Daniel Carter|--
How to Trade Gold CFDs: A Beginner’s Guide to XAU/USD Trading

How to Trade Gold CFDs: A Beginner’s Guide to XAU/USD Trading

Daniel Carter|--
Recommended Topics
markets.com